NeuroSigma plans $50m IPO to advance neurostimulation device
This article was originally published in Clinica
Executive Summary
Californian company NeuroSigma has filed for a $50m initial public offering to fund development of its Monarch external trigeminal nerve stimulation system (eTNS) system for epilepsy and depression. The firm, which plans to trade on the Nasdaq under the ticker symbol NSIG, did not give any pricing details.